[Inhibitors] "Keillor TG2 Inhibitors" (acrylamide compounds)_ZEDIRA - 코아사이언스

안녕하세요!

ZEDIRA GmbH 수입/공급 업체 코아사이언스 입니다.

 

자세한 상품 정보 및 관련 문의는 전화 02-858-0328 또는 info@coresciences.co.kr로 문의주시기 바랍니다.

감사합니다!

 

"Keillor TG2 Inhibitors" (acrylamide compounds)

​

Compounds AA9 (Z015), NC9 (Z016), and VA4 (Z017) were developed and produced by Dr. Jeffrey Keillor, Department of Chemistry and Biomolecular Sciences, University of Ottawa, Canada. The mechanism-based blockers carry an irreversibly acting acrylamide warhead linked to a lysine side chain. The NC9 and VA4 compounds are valuable tools shown to lock TG2 in the open conformation in vitro and in living cells, and to abolish GTP binding. Further, the molecules halt the proliferation and invasion of cancer stem cells. Find more details in the respective product data sheet (PDS).

​

The “Keillor TG2 Inhibitors” bear an acrylamide warhead, being attacked by the active site cysteine residue (1) to form an irreversible complex (2, 3).

Cat. No.	Name	Unit
Z015	Keillor inhibitor AA9	10 mg
Z016	Keillor inhibitor NC9	10 mg
Z017	Keillor inhibitor VA4	10 mg

​* 본 상품은 오직 연구용으로만 사용 가능합니다. 인체 및 제품화에 사용하실 수 없습니다.

코아사이언스 coresciences​ ZEDIRA GmbH, Darmstadt, Germany Korea 한국 대리점 distributor 트랜스글루타미나제 트랜스글루타미나아제 트랜스글루타미네이스 트랜스글루타미네이즈 활성 분석 측정 키트